Sutro Biopharma, Inc. STRO
9.53 USD +0.42 (+4.61%)
Nov 3, 2026, 3:47 PM EST
9.03 Day range 9.84
7.15 52-week range 43.85
- YTD
- -17.63%
- 1 year
- -13.36%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 11.50 +20.7% upside
Now 9.53
- Target (low)
- 4.00
- Target (mean)
- 11.50
- Target (high)
- 20.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy3
- Buy7
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.955 | -1.13 – -0.78 | 0.498 | -291.8% | 12.18M | -89.3% | 2 |
| Next quarter | -0.92 | -0.92 – -0.92 | -0.89 | -3.4% | 9.00M | -30.8% | 1 |
| Current year | -3.07 | -3.22 – -2.92 | -1.73 | -77.4% | 59.20M | -61.5% | 2 |
| Next year | -3.42 | -3.90 – -2.93 | -3.07 | -11.2% | 49.20M | -16.9% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Dec 11, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 11, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 16, 2024 | Truist Securities | Maintained | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 14, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 8, 2024 | B of A Securities | Initiated | — | Buy |
| Apr 3, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 3, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 3, 2024 | Truist Securities | Maintained | Buy | Buy |
| Apr 3, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Mar 28, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 27, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 26, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Mar 26, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Mar 26, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 15, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 14, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 9, 2023 | Deutsche Bank | Initiated | — | Buy |
| Oct 23, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 6, 2023 | Oppenheimer | Initiated | — | Outperform |
| Sep 6, 2023 | Truist Securities | Reiterated | Buy | Buy |
| Aug 14, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |